The useful question is not “Is this a good drug?” It is: what is the cheapest credible experiment that can change the decision?
Drug development can become a stack of inherited assumptions: customary CRO scope, customary sites, customary geographies, customary visits, customary endpoints, customary budgets.
Cheap-to-Truth works backward from the decision. What evidence would make us continue, stop, license, redesign or walk away? Then we hunt for the smallest valid path to that evidence.
Cheap does not beat valid. Fast does not beat safe. Safety, scientific validity, rights clarity and regulator usability are hard gates.
Score an asset + indication. Change the assumptions. Watch the opportunity change. This demo is synthetic and deterministic. UNKNOWN stays UNKNOWN.
This demo does not research the asset. Real diligence replaces assumptions with sourced evidence, documents uncertainty and red-teams the conclusion.
$4,950 one time
One asset + one indication. A bounded, decision-oriented diligence sprint. The deliverable is not a pile of research. It is an argument you can attack.
Book securely with StripeAfter payment, scope and kickoff are confirmed before substantive work begins. If the requested scope materially exceeds this offer, we will resolve it before starting.
We can help search for stranded, shelved or under-resourced assets that fit a defined Cheap-to-Truth thesis, then help make the owner, rights and trial economics legible.
Any sourcing fee, success fee or contingent compensation is negotiated separately in writing before work begins.
Discuss a sourcing mandate →For the rare opportunity where the asset, rights, evidence and capital all line up, the diligence machine can become an operating machine: one lean program, explicit gates, outsourced specialist execution, and capital released only against evidence.
This is a negotiated operating structure, not an offer of securities and not part of the $4,950 checkout.
Discuss a build →Not a CRO quote. We are interrogating whether the inherited trial structure deserves to exist.
Not a clinical recommendation. This is research and strategic diligence, not patient care.
Not investment advice. Commercial upside is one variable, not a recommendation to buy or sell anything.
Not a regulatory guarantee. A regulator decides what evidence it accepts.
Not “AI says so.” The work must be inspectable, sourced and able to survive a hostile read.
Not certainty laundering. UNKNOWN remains UNKNOWN until evidence changes it.
Often: prior human data, a plausible mechanism, a common or reachable population, an objective or fast endpoint, tolerable safety, manageable dosing and a realistic rights path. But the machine is built to expose exceptions rather than enforce a single template.
No. The sprint can start from an asset + indication thesis. If a protocol exists, it becomes evidence to interrogate rather than an untouchable starting assumption.
No. The purpose is to find and test the cost structure before capital is committed. Some programs are expensive because the science genuinely requires it.
We confirm the asset, indication, question to be answered, available source material, conflicts and scope. Then the diligence begins.